[Edaily Reporter Lee Hye-ra] #Samsung Electro-Mechanics is showing a gain of over 9% in early trading. According to MP Doctor on the 9th, as of 9:01 a.m. today, Samsung Electro-Mechanics is trading at 1,827,000 won, up 9.25% from the previous trading day. This surge in buying interest is believed to stem from positive sentiment in the securities market, which sees significant potential for upward revisions to profit estimates due to business growth—particularly in multilayer ceramic capacitors (MLCCs)—driven by expanding demand for artificial intelligence (AI).A panoramic view of Samsung Electro-Mechanics’ Suwon plant. (Photo courtesy of Samsung Electro-Mechanics) iM Securities raised its target price for Samsung Electro-Mechanics from 1.8 million won to 2.3 million won, a 28% increase. Park Jeong-ha, an analyst at iM Securities, stated in a report released today, “The company is a leading AI component stock poised to benefit simultaneously from its MLCC and high-density package semiconductor substrate (FC-BGA) businesses,” adding, “There is a high likelihood that earnings estimates will continue to rise significantly through additional price hikes and orders for silicon capacitors (SiCap).” Park highlighted the following as key investment points: △improving MLCC market conditions △growth potential for silicon capacitors △growth potential for FC-BGA. Accordingly, he projected Samsung Electro-Mechanics’ operating profit for next year and 2028 at 3.3 trillion won and 4.3 trillion won, respectively. Analyst Park emphasized, “It is necessary to focus on the potential for further upward revisions to earnings estimates rather than short-term stock price volatility.”
OGQ, South Korea’s largest intellectual property (IP) content company, which faces the risk of a forced sale of its founder’s shares due to a dispute with existing investors, has received an “A” ratin…
The home shopping industry, whose growth has stalled due to an economic downturn and a shrinking TV market, is seeking new avenues for growth beyond television. The industry is strengthening its onlin…
SK BIOPHARMACEUTICALS’ New Epilepsy Drug Excofry (Photo courtesy of SK BIOPHARMACEUTICALS)
The success or failure of new drug development no longer ends with obtaining approval. “IP management” ha…